March 22, 2023

Elacestant Significantly Improves Survival in Metastatic Breast Cancer
The standard of care for the management of estrogen receptor–positive, human epidermal growth factor receptor 2–negative metastatic or advanced breast cancer involves the use of endocrine therapy (i.e., either aromatase inhibitors or fulvestrant, along with a cyclin-dependent kinase inhibitor). Further disease progression while on this regimen is associated with endocrine therapy resistance and poor progression-free survival. Read more.


Occurrence of Dysgeusia Among Chemotherapy-Treated Breast Cancer Patients
Dysgeusia, which is an abnormal or impaired sense of taste, is a well-known adverse effect of cancer chemotherapy. Dysgeusia can adversely affect nutritional status, disease progression, healing, and overall quality of life in cancer patients, including those with breast cancer. Unfortunately, standardized methods to assess for taste alterations are lacking, which often leads to inaccurate estimates of this adverse event’s occurrence. Read more.

BC Risk in Transgender Women on Hormonal Therapy
Hormonal agents are administered to transgender persons to reduce psychological distress and to induce and maintain desired physical changes. There is little known about the risk of these hormones on breast development or on the risk of developing breast cancer (BC) among transgender women. A study focused on breast development in cisgender and transgender patients and compared them in terms of hormonal influences. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App